Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: Comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay

Journal of Clinical Microbiology

Volumn 48, Issue 5, 2010, Pages 1555-1561

  Wagner, Thor A ^a,b   Kress, Catherine M ^a   Beck, Ingrid ^b   Techapornroong, Malee ^e   Wittayapraparat, Pakorn ^f   Tansuphasawasdikul, Somboon ^g   Jourdain, Gonzague ^c,d   Ngo Giang Huong, Nicole ^c,d   Lallemant, Marc ^c,d   Frenkel, Lisa M ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e CHIANG MAI UNIVERSITY   (Thailand)

^f Chachoengsao Hospital   (Thailand)

^g BUDDHACHINARAJ HOSPITAL   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; NEVIRAPINE; RNA; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; ASSAY; BLOOD SAMPLING; CODON; CONSENSUS SEQUENCE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NONHUMAN; OLIGONUCLEOTIDE LIGATION ASSAY; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADULT; ANTI-HIV AGENTS; CHEMOPREVENTION; DNA PRIMERS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LIGASE CHAIN REACTION; MICROBIAL SENSITIVITY TESTS; NEVIRAPINE; OLIGONUCLEOTIDE PROBES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77951773576     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.02062-09     Document Type: Article

References (29)

1. Arvold, N. D., N. Ngo-Giang-Huong, K. McIntosh, V. Suraseranivong, B. Warachit, S. Piyaworawong, T. Changchit, M. Lallemant, and G. Jourdain. 2007. Maternal HIV-1 DNA load and mother-to-child transmission. AIDS Patient Care STDS 21:638-643. (Pubitemid 47525386)
2. Balzarini, J., A. Karlsson, M.-J. Pérez-Pérez, M. J. Camarasa, W. G. Tarpley, and E. De Clercq. 1993. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J. Virol. 67:5353-5359. (Pubitemid 23241368)
3. Beck, I. A., C. Crowell, R. Kittoe, H. Bredell, M. Machaba, C. Willamson, W. Janssens, S. Jallow, G. van der Groen, Y. Shao, M. Jacob, N. M. Samuel, I. L. de Rivera, N. Ngo-Giang-Huong, S. Cassol, G. Alemnji, and L. M. Frenkel. 2008. Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants. J. Acquir. Immune Defic. Syndr. 48:418-427.
4. Bi, X., H. Gatanaga, S. Ida, K. Tsuchiya, S. Matsuoka-Aizawa, S. Kimura, and S. Oka. 2003. Emergence of protease inhibitor resistance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year. J. Acquir. Immune Defic. Syndr. 34:1-6.
5. Coovadia, A., G. Hunt, E. J. Abrams, G. Sherman, T. Meyers, G. Barry, E. Malan, B. Marais, R. Stehlau, J. Ledwaba, S. M. Hammer, L. Morris, and L. Kuhn. 2009. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin. Infect. Dis. 48:462-472.
6. Ellis, G. M., M. Mahalanabis, I. A. Beck, G. Pepper, A. Wright, S. Hamilton, S. Holte, W. E. Naugler, D. M. Pawluk, C. Li, and L. M. Frenkel. 2004. Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J. Clin. Microbiol. 42: 3670-3674.
7. Eshleman, S. H., L. A. Guay, A. Mwatha, S. P. Cunningham, E. R. Brown, P. Musoke, F. Mmiro, and J. B. Jackson. 2004. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days versus 6-8 weeks after single-dose NVP prophylaxis: HIVNET 012. AIDS Res. Hum. Retroviruses 20: 595-599.
8. Flys, T., D. V. Nissley, C. W. Claasen, D. Jones, C. Shi, L. A. Guay, P. Musoke, F. Mmiro, J. N. Strathern, J. B. Jackson, J. R. Eshleman, and S. H. Eshleman. 2005. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J. Infect. Dis. 192:24-29.
9. Flys, T. S., S. Chen, D. C. Jones, D. R. Hoover, J. D. Church, S. A. Fiscus, A. Mwatha, L. A. Guay, F. Mmiro, P. Musoke, N. Kumwenda, T. E. Taha, J. B. Jackson, and S. H. Eshleman. 2006. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J. Acquir. Immune Defic. Syndr. 42:610-613.
10. Flys, T. S., D. Donnell, A. Mwatha, C. Nakabiito, P. Musoke, F. Mmiro, J. B. Jackson, L. A. Guay, and S. H. Eshleman. 2007. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J. Infect. Dis. 195:711-715.
11. Frenkel, L. M., L. E. Wagner, S. M. Atwood, T. J. Cummins, and S. Dewhurst. 1995. Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. J. Clin. Microbiol. 33:342-347.
12. Jackson, J. B., P. Musoke, T. Fleming, L. A. Guay, D. Bagenda, M. Allen, C. Nakabiito, J. Sherman, P. Bakaki, M. Owor, C. Ducar, M. Deseyve, A. Mwatha, L. Emel, C. Duefield, M. Mirochnick, M. G. Fowler, L. Mofenson, P. Miotti, M. Gigliotti, D. Bray, and F. Mmiro. 2003. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 362:859-868.
13. Johnson, J. A., J. Li, X. Wei, J. Lipscomb, D. Irlbeck, C. Craig, A. Smith, D. E. Bennett, M. Monsour, P. Sandstrom, E. R. Lanier, and W. Heneine. 2008. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med. 5:e158.
14. Johnson, V. A., F. Brun-Vezinet, B. Clotet, H. F. Gunthard, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. 2008. Update of the drug resistance mutations in HIV-1. Top. HIV Med. 16:138-145.
15. Jourdain, G., N. Ngo-Giang-Huong, S. Le Coeur, C. Bowonwatanuwong, P. Kantipong, P. Leechanachai, S. Ariyadej, P. Leenasirimakul, S. Hammer, and M. Lallemant. 2004. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N. Engl. J. Med. 351:229-240.
16. Kuritzkes, D. R., C. M. Lalama, H. J. Ribaudo, M. Marcial, W. A. Meyer, C. Shikuma, V. A. Johnson, S. A. Fiscus, R. T. D'Aquila, B. R. Schackman, E. P. Acosta, and R. M. Gulick. 2008. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J. Infect. Dis. 197:867-870.
17. Lallemant, M., G. Jourdain, S. Le Coeur, J. Y. Mary, N. Ngo-Giang-Huong, S. Koetsawang, S. Kanshana, K. McIntosh, and V. Thaineua. 2004. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-tochild transmission of HIV-1 in Thailand. N. Engl. J. Med. 351:217-228.
18. Lalonde, M. S., R. M. Troyer, A. R. Syed, S. Bulime, K. Demers, F. Bajunirwe, and E. J. Arts. 2007. Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies. J. Clin. Microbiol. 45:2604-2615.
19. Larder, B. A., P. Kellam, and S. D. Kemp. 1991. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 5:137-144.
20. Lockman, S., and A5208/OCTANE Study Team. 2009. Lopinavir/ritonavir+ tenofovir/emtricitabine is superior to nevirapine+tenofovir/emtricitabine for women with prior exposure to single-dose nevirapine: A5208 ("OCTANE"), abstr. 94LB. 16th Conf. Retrovir. Oppor. Infect., Montreal, Canada.
21. Lockman, S., R. L. Shapiro, L. M. Smeaton, C. Wester, I. Thior, L. Stevens, F. Chand, J. Makhema, C. Moffat, A. Asmelash, P. Ndase, P. Arimi, E. van Widenfelt, L. Mazhani, V. Novitsky, S. Lagakos, and M. Essex. 2007. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N. Engl. J. Med. 356:135-147.
22. Loubser, S., P. Balfe, G. Sherman, S. Hammer, L. Kuhn, and L. Morris. 2006. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 20:995-1002.
23. Metzner, K. J., S. G. Giulieri, S. A. Knoepfel, P. Rauch, P. Burgisser, S. Yerly, H. F. Günthard, and M. Cavassini. 2009. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin. Infect. Dis. 48:239-247.
24. Nowak, M. A., S. Bonhoeffer, G. M. Shaw, and R. M. May. 1997. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J. Theor. Biol. 184:203-217.
25. Perelson, A. S., P. Essunger, Y. Cao, M. Vesanen, A. Hurley, K. Saksela, M. Markowitz, and D. D. Ho. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-191.
26. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, and D. Pauletti. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666. (Pubitemid 24065732)
27. Schuurman, R., L. Demeter, P. Reichelderfer, J. Tijnagel, T. de Groot, and C. Boucher. 1999. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J. Clin. Microbiol. 37:2291-2296.
28. Simen, B. B., J. F. Simons, K. H. Hullsiek, R. M. Novak, R. D. Macarthur, J. D. Baxter, C. Huang, C. Lubeski, G. S. Turenchalk, M. S. Braverman, B. Desany, J. M. Rothberg, M. Egholm, and M. J. Kozal. 2009. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J. Infect. Dis. 199:693-701.
29. Weidle, P., J. Stringer, M. McConnell, J. Kiarie, T. Anekthananon, T. Jariyasethpong, D. Potter, W. Mutsotso, C. Borkowf, O. Bolu, and the NNRTI Response Study Team. 2008. Effectiveness of NNRTI-containing ART in women previously exposed to a single dose of nevirapine: a multi-country cohort study, abstr. 48. 15th Conf. Retrovir. Oppor. Infect., Boston, MA.